BR0112417A - Composições farmacêuticas contendo composto dds - Google Patents

Composições farmacêuticas contendo composto dds

Info

Publication number
BR0112417A
BR0112417A BR0112417-0A BR0112417A BR0112417A BR 0112417 A BR0112417 A BR 0112417A BR 0112417 A BR0112417 A BR 0112417A BR 0112417 A BR0112417 A BR 0112417A
Authority
BR
Brazil
Prior art keywords
compositions containing
pharmaceutical compositions
compound
dds compound
containing dds
Prior art date
Application number
BR0112417-0A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of BR0112417A publication Critical patent/BR0112417A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

"COMPOSIçõES FARMACêUTICAS CONTENDO COMPOSTO DDS". Uma composição farmacêutica tendo estabilidade assegurada de preservação, a qual contém um composto, onde um derivado de polissacarídeos tendo um grupo de carboxila é ligado a um derivado de camptotecina através de um espaçador ou sem ser mediado por espaçador, e um açúcar ou álcool de açúcar opcionalmente juntamente com uma substância para ajuste de pH.
BR0112417-0A 2000-07-13 2001-07-11 Composições farmacêuticas contendo composto dds BR0112417A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000213083 2000-07-13
PCT/JP2001/006020 WO2002005855A1 (fr) 2000-07-13 2001-07-11 Compositions pharmaceutiques contenant des composes dds

Publications (1)

Publication Number Publication Date
BR0112417A true BR0112417A (pt) 2003-07-01

Family

ID=18708899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112417-0A BR0112417A (pt) 2000-07-13 2001-07-11 Composições farmacêuticas contendo composto dds

Country Status (12)

Country Link
US (1) US6815435B2 (pt)
EP (1) EP1308171A1 (pt)
KR (1) KR20030023697A (pt)
CN (1) CN1556712A (pt)
AR (1) AR031714A1 (pt)
AU (1) AU2001271037A1 (pt)
BR (1) BR0112417A (pt)
CA (1) CA2415922A1 (pt)
MX (1) MXPA03000387A (pt)
NO (1) NO20030139L (pt)
RU (1) RU2003100532A (pt)
WO (1) WO2002005855A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030031502A (ko) * 2000-06-29 2003-04-21 다이이찌 세이야꾸 가부시기가이샤 디디에스 화합물 및 그의 제조방법
TWI320713B (pt) 2001-06-01 2010-02-21 Neochemir Inc
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
AU2003289234A1 (en) * 2002-12-10 2004-06-30 Masaya Tanaka Skin material for external use and antiprutiric agent for external use and wrinkle-reducing instrument using the same
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
JP5736031B2 (ja) 2010-03-29 2015-06-17 フェリング ベスローテン フェンノートシャップ 速溶解性医薬組成物
AU2013263795B2 (en) * 2010-03-29 2015-09-17 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AU2012307530B2 (en) * 2011-09-16 2016-12-08 Ferring B.V. A fast dissolving pharmaceutical composition
EP3632471A1 (en) 2012-10-11 2020-04-08 Daiichi Sankyo Company, Limited Antibody-drug conjugate
JP6272230B2 (ja) 2012-10-19 2018-01-31 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート
SI3088419T1 (sl) 2013-12-25 2019-01-31 Daiichi Sankyo Company Zdravilni konjugat anti trop2 protitelesa
KR20230162159A (ko) 2014-01-31 2023-11-28 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
IL300540B1 (en) 2014-04-10 2024-04-01 Daiichi Sankyo Co Ltd Preparation method for drug conjugates - antibody against - HER3
US9855339B2 (en) 2014-12-26 2018-01-02 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
KR20180039628A (ko) * 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 조성물
KR20180114027A (ko) 2016-03-01 2018-10-17 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 제제
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
CN114341162A (zh) 2019-07-10 2022-04-12 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
KR20220051332A (ko) 2019-07-10 2022-04-26 싸이브렉사 3, 인크. 치료제로서의 미세소관 표적화제의 펩티드 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
EP0857484A4 (en) 1995-09-13 2000-12-06 Nippon Shinyaku Co Ltd PGE1- FREEZING DRIED PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
IL125800A0 (en) * 1996-02-19 1999-04-11 Nycomed Imaging As Thermally stabilized contrast agent
AU2034097A (en) * 1996-03-19 1997-10-10 Morgan Crucible Company Plc, The A conduit
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CA2345612A1 (en) 1998-09-29 2000-04-06 Masao Nagao Anti-fungal composition

Also Published As

Publication number Publication date
AU2001271037A1 (en) 2002-01-30
MXPA03000387A (es) 2003-09-22
US6815435B2 (en) 2004-11-09
EP1308171A1 (en) 2003-05-07
NO20030139D0 (no) 2003-01-10
WO2002005855A1 (fr) 2002-01-24
NO20030139L (no) 2003-03-13
US20030148931A1 (en) 2003-08-07
RU2003100532A (ru) 2004-07-20
CA2415922A1 (en) 2002-01-24
CN1556712A (zh) 2004-12-22
KR20030023697A (ko) 2003-03-19
AR031714A1 (es) 2003-10-01

Similar Documents

Publication Publication Date Title
BR0112417A (pt) Composições farmacêuticas contendo composto dds
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
HRP20020880B1 (en) New pharmaceutical composition
CY1105388T1 (el) Μορφη δοσολογιας πepιλαμβανουσα θepαπευτικο σκευασμα
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
BR9810495A (pt) Composição farmacêutica
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
NZ501950A (en) Medicinal compositions for application to mucosa
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
BRPI0110024B8 (pt) derivados de ecteinascidina antitumorais, composição farmacêutica que os compreende e uso dos mesmos
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
DE602004019405D1 (de) Pharmazeutische zubereitungen
HUP0103431A2 (hu) 5-HT4 receptor agonista vagy antagonista hatóanyagot tartalmazó, orális gyógyászati készítmény
ME00083B (me) Farmaceutski oblik dronedarona za parenteralnu upotrebu
YU59201A (sh) Matrica koja se može direktno komprimovati, za kontrolisano oslobadjanje pojedinačnih dnevnih doza klaritromicina
YU47338B (sh) Novo jedinjenje 4-fluoro-2-// (4-metoksi-2-piridinil)metil-/sulfinil/- 1h-benzimidazol i postupak za njegovo dobijanje
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
WO2001022917A3 (en) Effervescent compositions comprising nimesulide
BR0109891A (pt) Composição farmaceutica contendo derivado de camptotecina e substância de ajuste de ph
AR012972A1 (es) Forma farmaceutica para la administracion de paclitaxel, proceso para la preparacion de una composicion de paclitaxel lista para usar y uso de estacomposicion
KR900015732A (ko) 경구용 제제

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4745 (2006.01), A61K 9/00 (2006.01), A61K